MediWound Ltd. (NasdaqGM: MDWD)
Health Care · Pharmaceuticals · IL
$12.70
-3.86% today · -25.0% 1Y
MediWound Ltd. (NasdaqGM: MDWD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $170.54M and employs 121 people.
Over the last twelve months the share price has lost 25.0%, trading between 13.06 and 20.30.
Tweenvest scores MediWound Ltd. across four factors: quality 32/100, value 39/100, growth 0/100. Its strongest factor is value.
MDWD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $170.54M
- Revenue (TTM)
- $11.86M
- P/E
- —
- EPS
- -2.25
- Dividend yield
- —
- Beta (5Y)
- 0.16
- 52-week high
- $20.30
- 52-week low
- $13.06
- Avg volume (3M)
- —
- Shares outstanding
- 12.91M
- Employees
- 121
- Next earnings
- —
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
- ISIN
- IL0011316309
- Founded
- 2000
- Listed since
- Mar 20, 2014
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.